Understanding the Burden of Nosocomial Infections
Hospital-acquired infections, also known as nosocomial infections, represent one of the most significant challenges in modern medicine, particularly within the Intensive Care Unit (ICU). Patients in the ICU are often at their most vulnerable, frequently requiring invasive procedures such as central venous catheterization, urinary catheterization, and mechanical ventilation. While these interventions are life-saving, they also serve as potential gateways for pathogens. Common nosocomial infections include Central Line-Associated Bloodstream Infections (CLABSI), Catheter-Associated Urinary Tract Infections (CAUTI), and Ventilator-Associated Pneumonia (VAP). Beyond the direct clinical impact on the patient, these infections lead to prolonged hospital stays, increased healthcare costs, and a higher risk of mortality. Furthermore, the rise of multi-drug resistant organisms (MDROs) has made treating these infections increasingly difficult, necessitating the use of stronger, broader-spectrum antibiotics that contribute to the global crisis of antimicrobial resistance.
The Role of Chlorhexidine in Infection Prevention
Chlorhexidine gluconate is a potent antiseptic agent known for its broad-spectrum activity against a wide range of bacteria, fungi, and some viruses. It works by disrupting the cell membranes of microorganisms, leading to their death. In many clinical settings, chlorhexidine has been used as a skin preparation before surgery or during the insertion of vascular catheters. The concept of daily chlorhexidine bathing for ICU patients emerged as a strategy to reduce the microbial load on the skin, thereby preventing the translocation of bacteria into the bloodstream or other sterile sites. Previous studies had shown mixed results regarding its efficacy, leading to the development of the CLEAN-IT trial to provide more definitive evidence in a diverse clinical setting.
The CLEAN-IT Trial: Study Design and Methodology
The Daily Chlorhexidine Bathing for the Prevention of Nosocomial Infections in Critically Ill Patients (CLEAN-IT) trial was a robust, open-label, cluster-randomised crossover trial conducted across 22 intensive care units in Brazil. The study aimed to compare the effects of daily bathing with 2 percent chlorhexidine gluconate against standard bathing practices using soap and water. In a cluster-randomised crossover design, entire ICUs are assigned to a specific intervention for a set period before switching to the alternative intervention after a designated washout period. In this study, centres were randomised to either 3 or 6 months of chlorhexidine bathing followed by 3 or 6 months of the control bathing (soap and water), with a 1-month washout period in between to ensure that the effects of the first intervention did not carry over into the second. The primary objective was to measure the rate of nosocomial infections, specifically focusing on CLABSI, CAUTI, and VAP. Secondary objectives included the incidence of multi-drug resistant cultures, overall antibiotic consumption, length of ICU stay, and patient mortality.
Participant Demographics and Baseline Characteristics
Between August 2022 and December 2023, the trial included a total of 15,935 patients. Of these, 8,247 were in the chlorhexidine group and 7,688 were in the control group. The demographics were well-balanced between the two groups. The mean age was approximately 64 years in both cohorts, with a nearly equal distribution of male and female patients (roughly 52 percent male in both). This large sample size provided significant statistical power to detect meaningful differences in infection rates and other clinical outcomes. The patients included were representative of a general ICU population, covering various underlying medical conditions and degrees of illness severity.
Primary Findings: Infection Rates
The primary outcome of the CLEAN-IT trial yielded surprising results. Contrary to some previous smaller studies, daily chlorhexidine bathing did not result in a statistically significant reduction in the overall rate of nosocomial infections. In the chlorhexidine group, there were 201 infections, representing a rate of 3.99 per 1,000 patient-days. In the control group, there were 165 infections, or 3.45 per 1,000 patient-days. The rate ratio was calculated at 1.09, with a p-value of 0.22, indicating that the difference between the groups could likely be attributed to chance. These findings suggest that while chlorhexidine is a powerful antiseptic, its use as a daily bath may not be a universal solution for preventing the most common types of ICU-acquired infections in all settings.
Impact on Multi-Drug Resistant Organisms
While the primary outcome did not show a reduction in total infections, a critical secondary outcome revealed a significant benefit. Patients bathed with chlorhexidine had substantially lower rates of multi-drug resistant (MDR) cultures compared to those in the control group. The rate in the chlorhexidine group was 14.42 per 1,000 patient-days, compared to 20.13 per 1,000 patient-days in the soap and water group. This resulted in a rate ratio of 0.73 (p = 0.0092), representing a 27 percent reduction in the isolation of MDR pathogens. This is a crucial finding, as MDR organisms are notoriously difficult to treat and are associated with worse patient outcomes. By reducing the colonization and isolation of these pathogens, chlorhexidine bathing may play a vital role in hospital environmental hygiene and the prevention of MDR outbreaks.
Antimicrobial Consumption and the AWaRe Classification
The researchers also examined the trial’s impact on antibiotic use, utilizing the World Health Organization’s (WHO) AWaRe classification system. This system categorizes antibiotics into three groups: Access (first-line treatments), Watch (medicines at higher risk of resistance), and Reserve (last-resort antibiotics for MDR infections). Although the overall consumption of antimicrobials did not differ significantly between the groups, there was a statistically significant 27 percent reduction in the use of ‘Reserve’ group antibiotics in the chlorhexidine group (rate-ratio 0.73, p = 0.0071). This suggests that while patients were still receiving antibiotics, the severity or type of suspected infections might have changed, allowing clinicians to avoid using the most potent, last-resort drugs. This qualitative shift in antimicrobial use is a positive step for antibiotic stewardship programs.
Safety, Mortality, and Length of Stay
A key concern with any intervention in the ICU is whether it impacts patient survival. The CLEAN-IT trial found no significant difference in mortality rates between the chlorhexidine and control groups. Furthermore, there was no difference in the length of ICU stay. These findings indicate that while chlorhexidine bathing might not have reduced the overall number of infections, it was safe and did not lead to adverse outcomes for the patients. The reduction in MDR cultures and high-tier antibiotic use occurred without any negative impact on the patients’ overall recovery or survival.
Interpretation and Clinical Implications
The interpretation of the CLEAN-IT trial requires a nuanced look at the data. On one hand, the lack of reduction in the primary infection rate suggests that standard infection control bundles—which include hand hygiene, proper catheter care, and head-of-bed elevation—remain the cornerstone of prevention, and chlorhexidine bathing may not add an incremental benefit to those specific metrics in this population. On the other hand, the reduction in MDR pathogen isolation and ‘Reserve’ antibiotic use is a major finding. In an era where antimicrobial resistance is a global health threat, any intervention that reduces the need for last-resort antibiotics is highly valuable. Clinicians and hospital administrators may consider chlorhexidine bathing not necessarily as a tool to lower the raw number of infections, but as a strategic component of an antimicrobial stewardship and MDR control program.
Future Directions in ICU Hygiene
The results of the CLEAN-IT trial highlight the complexity of infection control in the ICU. Future research may focus on identifying specific sub-populations of patients who benefit most from chlorhexidine bathing, such as those with prolonged stays or those in units with high endemic rates of specific MDR organisms. Additionally, further studies could investigate the long-term impact of widespread chlorhexidine use on the potential development of antiseptic resistance. For now, the CLEAN-IT trial provides high-quality evidence that helps refine our approach to ICU hygiene, emphasizing that while some interventions may not meet their primary goals, they can still offer significant benefits in the fight against antibiotic-resistant bacteria.
